Cardiff Oncology, Inc. (CRDF) vs OKYO Pharma Limited Sponsored ADR (OKYO)

Cardiff Oncology, Inc. and OKYO Pharma Limited Sponsored ADR are both Biotechnology companies. Cardiff Oncology, Inc. and OKYO Pharma Limited Sponsored ADR are of similar size ($75.5M and $75.1M). OKYO Pharma Limited Sponsored ADR has the higher net margin (0.00% vs −7,889.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, OKYO Pharma Limited Sponsored ADR leads on 6 and Cardiff Oncology, Inc. on 5.

Valuation

Metric CRDF OKYO Biotechnology median
P/E n/m n/m 8.50
P/S 122.52 n/m 9.71
P/B 2.35 86.44 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 57.34 n/m 9.21
Earnings yield (65.93%) 0.00% (33.15%)
Free cash flow yield (65.78%) (0.89%) (25.50%)

Profitability

Metric CRDF OKYO Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (8,320.08%) — 0.00%
Net margin (7,888.98%) 0.00% 0.00%
Free cash flow margin (8,059.45%) 0.00% 0.00%
Return on equity (94.14%) 0.00% (56.36%)
Return on assets (70.89%) 0.00% (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CRDF OKYO Biotechnology median
Revenue growth (TTM) (6.79%) — 6.02%
EPS growth (last fiscal year) 27.37% (101.34%) 30.26%
Revenue growth, 5-year CAGR 10.13% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRDF OKYO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.30 2.43 4.72
Net debt to EBITDA 1.18 2.42 0.96

Dividend

Metric CRDF OKYO Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CRDF OKYO Biotechnology median
Market cap 75.54m 75.05m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack